Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comprehensive Plasma Metabolomic and Lipidomic Profiling for Predictive Modeling and Biomarker Discovery of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitor-Treated Gastric Cancer Patients: A Prospective Cohort Study

NCT06915389 is registered in ClinicalTrials.gov with Qinghai Red Cross Hospital as lead sponsor.

NCT NCT06915389
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06915389 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comprehensive Plasma Metabolomic and Lipidomic Profiling for Predictive Modeling and Biomarker Discovery of Immune-Related Adverse Events in PD-1/PD-L1 Inhibitor-Treated Gastric Cancer Patients: A Prospective Cohort Study
Lead sponsor
Qinghai Red Cross Hospital
Phase
Observational
Overall status
Recruiting
Start date
February 22, 2025
Completion date
June 30, 2027
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adverse event, gastric cancer, immunotherapy, lipidomics, metabonomics